Monitoring high-risk patients for chemotherapy-related cardiotoxicity: A retrospective analysis

Table 1 Baseline characteristics of study patients, n (%)

Baseline characteristics	Total patients	Patients with cardiotoxicity	χ2 (P value)
	(n = 195)	(n = 17)
Sociodemographic characteristics
Male	108 (55.7)	11 (64.7)
Female	87 (44.6)	6 (35.3)	0.209
Smoking	29 (14.9)	3 (17.6)	0.442
Medical history
Hypertension	50 (25.8)	7 (41.2)	0.129
Dyslipidemia	17 (8.7)	2 (11.8)	0.384
Diabetes	23 (11.8)	4 (23.5)	0.113
Acute myorcardial infarction	7 (3.6)	0 (0.0)	NA
Atrial fibrillation	10 (5.1)	2 (11.8)	0.157
Heart failure	27 (13.9)	11 (64.7)	< 0.001
Peripheral vascular disease	24 (12.3)	2 (11,8)	0.421
Type of malignancy
Metastatic malignancy	54 (27.8)	4 (23.5)	0.278
Ongoing radiotherapy	47 (24.2)	4 (23.5)	0.398
Breast cancer	17 (8.7)	0 (0.0)	NA
Hodgkin lymphoma	7 (3.6)	0 (0.0)	NA
Non-Hodgkin lymphoma	78 (40.2)	7 (41.2)	0.416
Acute myeloid leukemia	11 (5.6)	4 (23.5)	0.005
Multiple myeloma	7 (3.6)	0 (0.0)	NA
Other non-hematologic malignances	55 (28.3)	3 (17.6)	0.127
Other hematologic malignances	19 (9.8)	3 (17.6)	0.192

NA: Not available.